Dear All,
I would like to inform you that 2 postdoctoral positions are available
at the EMBL Hamburg Unit in the research group of Matthias Wilmanns.
I attach brief descriptions of the Vacancy Notices below. Deadline for
application is 15th June 2012.
Further Detailed Information can be found under :
http://www.embl-hamburg.de/aboutus/jobs/searchjobs/index.php?newlang=1&newms=sr&searchregion=668
Regards
Margret Fischer
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
*Postdoctoral Positon, Reference HH_00025*
Applications are invited for research projects of the Wilmanns group in
the EC-funded consortium SystemTB (www.systemtb.org), which aims to
understand the pathology of /Mycobacterium tuberculosis/ during
infection. While the core expertise of our group is in structural
biology, we have established methods in mycobacterial genetics for the
creation of full deletion mutants and specific point mutants using
non-pathogenic model systems (M. smegmatis, BCG) (for examples, see:
Noens et al. (2011) PMID: 2143903, Poulsen et al. (2010) Mol. Syst.
Biol. PMID: 21439037). We have initialized several new collaborations
using different "--omics" techniques, namely in interactomics (using
high throughput mass spectrometry) (IBB Warsaw), metabolomics (ETH
Zurich), proteomics (ETH Zurich), and lipidomics (CNRS Toulouse). The
fellow is expected to carry out and to coordinate experiments in
mycobacterial genetics in the context of ongoing and future projects.
Most of them will be in cooperation with partners from the SystemTB
consortium
*
Postdoctoral Positon, Reference HH_00026*
Applications are invited for research projects of the Wilmanns group
(www.embl-hamburg.de/research/unit/wilmanns) in the new European
consortium GoMoA with partners from Spain, France and Germany. The key
aim of this network is to identify and to characterize protein targets
from /Mycobacterium tuberculosis/ for lead compounds against
tuberculosis that already have been validated by an industrial partner.
The objective of our group is to contribute to the identification of
protein targets, in collaboration with the group of Dr. John Overington
from the EMBL-EBI Unit in Cambridge (UK), and on their biochemical and
structural characterization. This novel research direction will
complement our record in M. tuberculosis structural biology and
functional characterization. The fellow is expected to carry out and to
coordinate experiments in functional and subsequent structural
characterization of protein targets from /M. tuberculos/
/
/